Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.
Also called NCT06174220
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Registry
-
NCT06174220
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Canada
- Registry status
- Recruiting
Technical summary
Registry record NCT06174220. Randomized; quadruple masking; primary purpose treatment. Start 2025-03-21 (actual); primary completion 2027-02-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
- Acronym
- TaRGET
- Condition
- Arrhythmogenic Cardiomyopathy
- Condition
- Arrhythmogenic Right Ventricular Cardiomyopathy
- Intervention (Drug)
- Tideglusib
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hamilton Health Sciences Corporation
- Collaborator
- Canadian Institutes of Health Research (CIHR)
- Collaborator
- Canadian SADS
- Collaborator
- AMO Pharma Limited
- Collaborator
- Hearts in Rhythm Organization (HiRO)
- Collaborator
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct06174220- Content hash
5b2880083c4ce9832e22ccd7a521279a26cb00be9b376f6395e730c8c92955fd